DermaSensor Patent Portfolio Analysis

One pulse, sixty-four months after the last

The $4M Series B came from Harmonix Fund, SternAegis and Pier 70 Ventures. It is the visible event. The invisible one is the gap behind it: the last public filing from DermaSensor is dated 21 May 2021, five years and four months before the money landed. Anything filed since then is still inside the publication window and cannot be read yet.

That gap is not automatically a silence. A company founded in 2009 that raises to commercialise is usually filing on the things it learned in the clinic, and those applications sit unpublished for eighteen months. What the public record can tell you is what the company chose to protect when it had no revenue to defend, which is often the more revealing choice.

Nothing waiting, everything already decided

Most early-stage portfolios skew the other way: a thin band of granted rights and a thick queue of pending applications carrying the hopes. Here the queue is empty. Two families since 2013, two granted, zero published and pending. Every claim DermaSensor holds in public has been through examination and survived it. There is no application still being argued with.

That has a plain consequence. Both families are enforceable today, not in 2027. It also means the public scope is fixed: what the examiner allowed is what there is, with no continuation visible to broaden or redirect it. The filings are US only. The titles point at one idea, examined twice: calibrating light intensity, and optical detection of melanoma by elastic scattering.

Two families, two grants, nothing pending. The public scope is already settled.

Six names, and nobody on both families

Six inventors are named across the portfolio. The most frequently named, Steven Ryan Freiden, appears on one of the two families. So do Warren Stewart Macchi and Cody Vance Simmons. No single person bridges 2013 and 2021. The highlighted dot is the top of a very flat distribution.

Read that against the eight-year gap and it looks less like a founding pair grinding at one problem and more like two distinct efforts on the same physics. The 2013 work established optical melanoma detection. The 2021 work addresses calibration of light intensity within such a system, which is the kind of problem you only meet after building hardware people have to use. Different problem, different bench, different names.

Two families on a scale built for hundreds

The same CPC groups have drawn Philips with 686 families over five years, Samsung with 644, Biosense Webster Israel with 388, Zhejiang University with 372, Medtronic with 289 and Huawei with 282. A61B, diagnosis and surgery, is where the large device and handset companies file. On this scale DermaSensor is a point. Even the same-week neighbours in A61B5, Covenant and Implicity, are filing into the same broad territory.

Count is the wrong measure in a space this dense, because nobody wins it by volume. What matters is whether the two granted sets of claims sit on the specific mechanism, elastic scattering spectroscopy applied to a skin lesion with calibrated illumination, or on something a large filer's general sensing work would pass through anyway. Narrow and mechanical beats broad and crowded.

Who found these patents, and from where

The citing set is small and not dermatological. Motion Engine accounts for seven citing publications, Curai three, Beylin Simon two, Mei Micro two and Tsme two. These are the organisations whose own applications pointed back at DermaSensor's work, and the shape of the list says the optical and sensing side of the disclosure is what other filers keep reaching for.

Citations are not a judgement of value, but they do mark where a document sits in the technical map. Being cited by sensing and MEMS-adjacent filers rather than by skin imaging companies suggests the 2013 and 2021 disclosures read, to examiners and drafters, as instrument physics. That is a durable place to own claims, because instrument physics does not go out of fashion when the clinical workflow changes.

What the hiring plan already answered

Forty-seven open roles: nineteen in bio and clinical, seventeen in go-to-market, five in ops and finance, four in software and AI. Regional sales managers for the West and the South East. Clinical solution specialists. This is a company staffing distribution and evidence generation, not a research expansion. Expect further filings, if any come, in the same claim space rather than a new one.

So the moat is thin in count and real in kind. Two granted US families, both live, both sitting on the optical mechanism, in a CPC neighbourhood where the giants file by the hundred and nobody's breadth decides anything. Whether that is enough depends entirely on how close the allowed claims sit to the thing being sold, and on what has been filed since May 2021 that nobody can read yet.

Thin in count, real in kind. Scope is the whole argument.